Australian Pharmaceuticals & Biotech Strong Balance Sheet Stocks

Syntara

Market Cap: AU$84.5m

Operates as a clinical-stage drug development company that focuses on blood-related cancers in Australia.

Imugene

Market Cap: AU$194.1m

A clinical stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumours in Australia.

Medical Developments International

Market Cap: AU$52.4m

Manufactures and distributes emergency medical solutions in Australia, Europe, the United States, and internationally.

Cynata Therapeutics

Market Cap: AU$44.1m

Engages in the development and commercialization of proprietary induced pluripotent stem cell and mesenchymal stem cell technology under the Cymerus brand for human therapeutic use in Australia.

Aroa Biosurgery

Market Cap: AU$146.6m

Develops, manufactures, and sells medical devices for wound and soft tissue repair using extracellular matrix (ECM) technology in the United States and internationally.

Mayne Pharma Group

Market Cap: AU$567.9m

A specialty pharmaceutical company, manufactures and sells branded and generic pharmaceutical products in Australia, New Zealand, the United States, Canada, Europe, Asia, and internationally.

Dimerix

Market Cap: AU$234.9m

A biopharmaceutical company, develops and commercializes pharmaceutical products for unmet medical needs in Australia.

Botanix Pharmaceuticals

Market Cap: AU$705.6m

Engages in the research and development of dermatology and antimicrobial products in Australia and the United States.

Genetic Signatures

Market Cap: AU$105.6m

Operates as a molecular diagnostic company in Australia, the Asia Pacific, Europe, the Middle East, Asia, and the Americas.

Beroni Group

Market Cap: AU$75.9m

Develops and sells smoking control products, air purifiers, water filters, cosmetics, stem-cell therapies, and health care products and supplements in Australia and internationally.

Paradigm Biopharmaceuticals

Market Cap: AU$122.7m

Engages in the research and development of therapeutic products for human use in Australia.

Trajan Group Holdings

Market Cap: AU$120.4m

Develops, manufactures, sells, and distributes analytical and life science products and devices in Australia, New Zealand, Malaysia, Japan, the United States, Europe, the Middle East, Africa, and India.

Anatara Lifesciences

Market Cap: AU$1.3m

Engages in the research, development, and commercialization of evidence-based solutions for gastrointestinal diseases in animals and humans in Australia.

OncoSil Medical

Market Cap: AU$18.4m

A medical device company, develops and commercializes localized radiation therapy for the treatment of pancreatic and distal cholangiocarcinoma in Australia, New Zealand, and Europe.

Vectus Biosystems

Market Cap: AU$4.3m

Engages in the medical research and development activities in Australia.

Proteomics International Laboratories

Market Cap: AU$58.3m

Operates as a medical technology company with a focus on the area of proteomics in Australia, New Zealand, the United States, Europe, India, and South East Asia.

Acrux

Market Cap: AU$9.0m

Engages in the development and commercialization of generic and topically applied pharmaceutical products in Australia, Europe, the United States, and internationally.

CSL

Market Cap: AU$117.1b

Researches, develops, manufactures, markets, and distributes biopharmaceutical and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally.

Genetic Technologies

Market Cap: AU$5.7m

A molecular diagnostics company, engages in the provision of predictive genetic testing and risk assessment tools to help physicians manage people’s health in the America, Canada, Europe, the Middle East, Africa, Latin America, and the Asia Pacific.

BCAL Diagnostics

Market Cap: AU$35.1m

A screening and diagnostic company, engages in developing a novel blood screening test to improve the diagnosis and monitoring of breast cancer.

Patrys

Market Cap: AU$6.2m

Develops and commercializes antibody technologies for the treatment of cancer in Australia.

Neurizon Therapeutics

Market Cap: AU$49.2m

A clinical stage biotechnology company, develops therapeutics for neurodegenerative diseases in Switzerland, Australia, the United States, and internationally.

Vitura Health

Market Cap: AU$46.4m

Engages in the sale and distribution of medicinal cannabis products in Australia.

Telix Pharmaceuticals

Market Cap: AU$8.7b

A commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals for cancer and rare diseases in Australia, Belgium, Japan, Switzerland, and the United States.